Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab tirumotecan + pembrolizumab + carboplatin
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is an investigational **combination therapy** comprising three agents: sacituzumab tirumotecan (MK-2870, also known as sac-TMT), pembrolizumab, and carboplatin. Sacituzumab tirumotecan is an **antibody-drug conjugate** that targets Trop-2 and delivers a topoisomerase I inhibitor payload (derivative KL610023). Pembrolizumab is a **monoclonal antibody** immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1/PD-L2 and thereby restoring T-cell activity against cancer. Carboplatin is a **small molecule platinum-based chemotherapy** that induces DNA cross-linking, resulting in cell apoptosis. This specific combination is being evaluated in clinical trials for the treatment of triple-negative breast cancer (TNBC) and metastatic squamous non-small cell lung cancer (NSCLC)[1][2][3][4][5][6][7][9].
- Other names
- sacituzumab tirumotecan + pembrolizumab + carboplatin
02
Targets
TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on sacituzumab tirumotecan + pembrolizumab + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab tirumotecan + pembrolizumab + carboplatin.